Antibody has ‘potent’ effects against AML

Micrograph showing AML
Image from Paulo
Henrique Orlandi Mourao
The bispecific antibody APVO436 has demonstrated robust T-cell activation with limited cytokine release in acute myeloid leukemia (AML), according to researchers. APVO436 binds CD123 and CD3 to redirect T-cell cytotoxicity against CD123-expressing tumor cells. Researchers found that APVO436 induced T-cell cytotoxicity in AML cells in vitro and in mouse models. In addition, levels of several cytokines were lower in experiments with APVO436 than in experiments with a comparator antibody. [Read Article]

Fostamatinib approved to treat adults with chronic ITP

Fostamatinib (Tavalisse)
Photo courtesy of
Rigel Pharmaceuticals
The US Food and Drug Administration (FDA) has granted approval for the oral SYK inhibitor fostamatinib disodium hexahydrate (Tavalisse™). Fostamatinib is now approved for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Rigel Pharmaceuticals, Inc., plans to launch fostamatinib in the US in late May 2018. [Read Article]

FDA expands approved use of product for VWD

Recombinant von Willebrand
factor (Vonvendi)
Photo courtesy of Shire
The US Food and Drug Administration (FDA) has expanded the approved use of Vonvendi, a recombinant von Willebrand factor product. Vonvendi is now approved for perioperative management of bleeding in adults (age 18 and older) with von Willebrand disease (VWD). Vonvendi was previously FDA-approved for on-demand treatment and control of bleeding episodes in adults with VWD. [Read Article]